QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Responses are durable for up to 5years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients 期刊论文 ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 卷号: 47, 期号: 9 作者:  Chuang, W. -L.;  Jia, J.;  Chan, H. L. Y.;  Han, K. -H.;  Tanwandee, T. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05 HBeAg seroconversion rates after 5 years of follow-up in patients treated with peginterferon alfa-2a (40KD) in NEPTUNE: Final results of the son of NEPTUNE long-term follow-up study 期刊论文 Hepatology International, 2017, 卷号: 11 作者:  Chuang W.-L., Jia J., Chan H.L.-Y., Han K.-H., Tanwandee T., Tan D., Chen X., Gane E.J., Piratvisuth T., Chen L., Xie Q., Sung J.J.-Y., Messinger D., Wat C., Bakalos G., Liaw Y.-F. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05 HBEAG SEROCONVERSION RATES AFTER FIVE YEARS OF FOLLOW-UP IN PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (40KD) IN NEPTUNE: FINAL RESULTS OF THE SON OF NEPTUNE LONG-TERM FOLLOW-UP STUDY 会议论文 作者:  Chuang, W. -L.;  Jia, J.;  Chan, H. L. -Y.;  Han, K. -H.;  Tanwandee, T. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC) 期刊论文 Journal of Clinical Oncology, 2016 作者:  Tanwandee T., Sukeepaisarnjaroen W., Chan S.L., Choo S., Han G., Sriuranpong V., Pan H., Yau T.C., Ren Z., Xu J.-M., Peng B., Saji T., Sun Y., Huang A., Manenti L., Qin S. 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05 Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial 期刊论文 Hepatology, 2014, 卷号: 60, 期号: 5, 页码: 1697-1707 作者:  Kudo, Masatoshi*;  Han, Guohong;  Finn, Richard S.;  Poon, Ronnie T. P.;  Blanc, Jean-Frederic 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/03 Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial 期刊论文 Hepatology, 2014, 卷号: Vol.60 No.5, 页码: 1697-1707 作者:  Kudo, M.;  Han, G.;  Finn, R.S.;  Poon, R.T.P.;  Blanc, J.-F. 收藏  |  浏览/下载：4/0  |  提交时间：2019/02/25 Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III Trial 期刊论文 HEPATOLOGY, 2014, 卷号: 60, 期号: 5 作者:  Kudo, Masatoshi;  Han, Guohong;  Finn, Richard S.;  Poon, Ronnie T. P.;  Blanc, Jean-Frederic 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/19 Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C 期刊论文 Hepatology, 2011, 卷号: 54, 期号: 5, 页码: 1591-1599 作者:  Liaw, Y. -F.*;  Jia, J. -D.;  Chan, H. L. Y.;  Han, K. H.;  Tanwandee, T. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/03 Shorter Durations and Lower Doses of Peginterferon alfa-2a Are Associated with Inferior Hepatitis B e Antigen Seroconversion Rates in Hepatitis B Virus Genotypes B or C 期刊论文 HEPATOLOGY, 2011, 卷号: 54, 期号: 5 作者:  Liaw, Y. -F.;  Jia, J. -D.;  Chan, H. L. Y.;  Han, K. H.;  Tanwandee, T. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/19